Cargando…
UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor
[Image: see text] We previously reported a potent small molecule Mer tyrosine kinase inhibitor UNC1062. However, its poor PK properties prevented further assessment in vivo. We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioa...
Autores principales: | Zhang, Weihe, DeRyckere, Deborah, Hunter, Debra, Liu, Jing, Stashko, Michael A., Minson, Katherine A., Cummings, Christopher T., Lee, Minjung, Glaros, Trevor G., Newton, Dianne L., Sather, Susan, Zhang, Dehui, Kireev, Dmitri, Janzen, William P., Earp, H. Shelton, Graham, Douglas K., Frye, Stephen V., Wang, Xiaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148167/ https://www.ncbi.nlm.nih.gov/pubmed/25068800 http://dx.doi.org/10.1021/jm500749d |
Ejemplares similares
-
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia
por: Lee-Sherick, Alisa B., et al.
Publicado: (2015) -
The Current State of FLT3 Inhibition in Acute Myeloid Leukemia – Pitfalls and Promises
por: Minson, Katherine A, et al.
Publicado: (2017) -
Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer
por: Cummings, Christopher T., et al.
Publicado: (2014) -
Targeting the TAM Receptors in Leukemia
por: Huey, Madeline G., et al.
Publicado: (2016) -
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
por: Yan, Dan, et al.
Publicado: (2021)